drugset
drugset / Trial / NCT05913570

Cadonilimab as Neoadjuvant Therapy in Resectable Stage II-III MSI-H/dMMR Colorectal Cancer

NCT05913570 ↗

Phase 2 Unknown 22 enrolled LiuYing
NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the safety, and tolerability of Cadonilimab as neoadjuvant treatment for resectable local advanced colorectal cancer patient with dMMR/MSI-H.

Timeline

Start
2023-06-20
Primary completion
2023-12-20
Completion
2023-12-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Cadonilimab Monoclonal antibody 10 mg/kg —

Indications

colorectal cancer mismatch repair cancer syndrome